Related Experiment Video

Updated: Jun 2, 2026

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis
11:44

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis

Published on: March 30, 2019

[MicroRNA-221 controls CDKN1C/P57 expression in human colorectal carcinoma]

Kai Sun1, Jun-jie Zeng, Wei Wang

  • 1Department of General Surgery, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China. sunkai9602@sina.com

Zhonghua Wei Chang Wai Ke Za Zhi = Chinese Journal of Gastrointestinal Surgery
|May 4, 2011
PubMed
Abstract

Insights

MicroRNA-221 (miR-221) is elevated in colorectal cancer (CRC) and suppresses CDKN1C/P57 protein, driving tumor growth. Inhibiting miR-221 may offer a new therapeutic strategy for CRC.

Area of Science:

  • Molecular oncology
  • Gene regulation
  • Cancer biology

Context:

  • Colorectal carcinoma (CRC) is a significant global health concern.
  • MicroRNAs play crucial roles in cancer development and progression.
  • Dysregulation of miR-221 and its targets is implicated in various cancers.

Purpose:

  • To investigate the expression of microRNA-221 (miR-221) and its target CDKN1C/P57 in colorectal carcinoma (CRC).
  • To evaluate the therapeutic potential of a miR-221 inhibitor on CRC cell proliferation and apoptosis.

Summary:

  • miR-221 was significantly upregulated in CRC tissues compared to adjacent non-cancerous tissues.
  • CDKN1C/P57 protein expression was markedly decreased in CRC, while mRNA levels showed no significant difference.
  • Inhibition of miR-221 enhanced CDKN1C/P57 protein expression, suppressed CRC cell proliferation, and induced apoptosis.

Impact:

  • miR-221 acts as an oncomiR by post-transcriptionally silencing CDKN1C/P57, promoting CRC.
  • A miR-221 inhibitor demonstrated potential in inhibiting CRC cell growth.
  • miR-221 inhibition represents a promising therapeutic target for colorectal cancer treatment.

More Related Videos

Detection of a Circulating MicroRNA Custom Panel in Patients with Metastatic Colorectal Cancer08:12

Detection of a Circulating MicroRNA Custom Panel in Patients with Metastatic Colorectal Cancer

Published on: March 14, 2019

Related Concept Videos

MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...
MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns—non-coding regions of a gene—or intergenic regions—stretches of DNA present between genes. Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA ends...
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
M-Cdk Drives Transition Into Mitosis02:15

M-Cdk Drives Transition Into Mitosis

Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...